This study aimed to investigate the risk of Parkinson’s disease (PD) among patients with age-related macular degeneration (AMD) and its association with confounding comorbidities.
Methods
A population-based retrospective cohort study was conducted using Longitudinal Health Insurance Database 2000 (LHID2000). We established AMD and non-AMD cohorts from January 1, 2000 to December 31, 2012 to determine the diagnosis of PD. A total of 20,848 patients were enrolled, with 10,424 AMD patients and 10,424 controls matched for age, sex, and index year at a 1:1 ratio. The follow-up period was from the index date of AMD diagnosis to the diagnosis of PD, death, withdrawal from the insurance program, or end of 2013. Multivariable Cox regression analysis was performed to examine the hazard ratio (HR) and 95% confidence interval (CI) for the risk of PD between the AMD and non-AMD cohorts.
Result
After adjusting for potential confounders, there was a higher risk of developing PD in the AMD cohort than in the non-AMD cohort (adjusted HR = 1.35, 95% CI = 1.16–1.58). A significant association could be observed in both female (aHR = 1.42, 95% CI = 1.13–1.80) and male (aHR = 1.28, 95% CI = 1.05–1.57) patients, aged more than 60 years (60–69: aHR = 1.51, 95% CI = 1.09–2.09, 70–79: aHR = 1.30, 95% CI = 1.05–1.60; 80–100: aHR = 1.40, 95% CI = 1.01–1.95), and with more than one comorbidity (aHR = 1.40, 95% CI = 1.20–1.64). A significant association between increased risk of PD and AMD was observed among patients with comorbidities of osteoporosis (aHR = 1.68, 95% CI = 1.22–2.33), diabetes (aHR = 1.41, 95% CI = 1.12–1.78) and hypertension (aHR = 1.36, 95% CI = 1.15–1.62) and medications of statin (aHR = 1.42, 95% CI = 1.19–1.69) and calcium channel blocker (CCB) (aHR = 1.32, 95% CI = 1.11–1.58). The cumulative incidence of PD was significantly higher over the 12-year follow-up period in AMD cohort (log-rank test, p < 0.001).
Conclusions
Patients with AMD may exhibit a higher risk of PD than those without AMD.
Hinweise
Po-Yu Jay Chen and Lei Wan contributed equally to this work.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Age-related macular degeneration (AMD) is one of the causes of blindness among the elderly, affecting the central area of the retina, causing thinning of the retinal pigment epithelium (RPE) and retinal nerve fiber layer (RNFL) [1]. Typically, AMD affects people older than 55 years [2]. Symptoms of AMD can range from asymptomatic to visual distortion and loss of central vision. Additionally, AMD is classified as neovascular or non-neovascular based on the presentation of growing abnormal blood vessels from either choroidal or retinal circulation [3]. Among those with non-neovascular AMD, the annual risk of developing neovascular AMD is about 1 to 4.7% [3].
On the other hand, PD is a central neural degenerative disorder among people aged around 40 years or older [4]. It mainly affects the motor system at the substantia nigra. It causes tremors, bradykinesia, rigidity, and other non-motor dysfunctions, such as cognitive and mood disorders. However, the exact pathogenesis of both AMD and PD remains unclear. It is worth noting that they share some risk factors in common, such as aging, but contain some other factors leading different direction of effect on them, such as sex and smoking [5‐7]. Though debatable, some researchers do classify both of them as a neurodegenerative disorder [5]. Besides, as the worldwide life expectancy extends, there is an increasing concern for these diseases. Therefore, further studies are important to understand the relationship between AMD and PD.
Anzeige
Several studies have reported a higher tendency for AMD patients to have PD [8, 9]. However, some of them did not adjust for other comorbidities which are often seen in the elderly, and for which Choi et al. [10] did adjust. Unlike previous studies, we aimed to include adequate adjustments to comorbidities and observe their relationship with PD. The purpose of this study was to further evaluate whether there is an increased risk of PD among AMD patients over a longer period, with a more precise subgroup analysis with adjustment for several comorbidities that are often seen among the elderly.
Methods
Data source
Taiwan’s National Health Insurance Research Database (NHIRD) was the source of the data used in this study. In addition, National Health Insurance (NHI) program, which was initiated in 1995 and covered 99.9% of Taiwan’s population of 23 million as of 2013, is the national medical insurance and healthcare system of Taiwan. NHIRD includes the data (such as demographic data, medical records, prescription records, and medical procedures) of those who sought medical care through the NHI program. More specifically, this study utilized data from the Longitudinal Health Insurance Database 2000 (LHID2000), which is a sub-database of the NHIRD and is consisted of 1 million people randomly selected from the NHIRD in 2000 [11‐13].
Sample participant
The study population was selected from LHID2000 data covering the period from January 1996 through December 2013. The clinical diagnoses included in the study were determined by licensed physicians and were made based on the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) Patients newly diagnosed with AMD (ICD-9-CM code: 362.50 Unspecified AMD, 362.51 Non-neovascular AMD, and 362.52 Neovascular AMD) between January 1998 and December 2012 were grouped into the AMD cohort. The date of diagnosis of AMD was used as the index date. Dates between 1998 and 2013 were allocated to the subjects in the non-AMD cohort as index dates. The index date for the non-AMD cohort was determined as follows: (1) Randomly assigning a month number for all people in the non-AMD cohort; (2) Giving them a numeric constant of 15 for the date of the month; (3) Alloting the year 1998 to all people in the non-AMD cohort, calculating their ages, and matching the strings of the calculated ages, gender, and year in the non-AMD cohort to the strings of the ages, gender, and year in the AMD cohort using 1:1 matching; (4) Excluding the matched people from the people in the non-AMD cohort; (5) Repeat the steps 3 and 4 using the year 1999, 2000, 2001, and so on until the year 2012; (6) Finally, each in the AMD cohort was matched with a person in the non-AMD cohort when using 1:1 matching. Starting with the index date, all subjects were followed up until the diagnosis of PD (ICD-9-CM code: 332 and A221), death, withdrawal from the insurance program, or the end of the study period on December 31, 2013. The exclusion criteria for the study were as follows: (1) patients aged between 0 and 49 years old since the index date; (2) patients with PD prior to the index dates. Ultimately, 10,424 AMD patients were enrolled in the AMD group. Subjects in the non-AMD cohort were randomly matched to the patients in the AMD cohort on the basis of age, sex, and index year of AMD diagnosis at a ratio of 1:1. A total of 10,424 subjects were matched.
Comorbidity and medication
The comorbidities analyzed in this study were osteoporosis (ICD-9-CM code: 733), diabetes (ICD-9-CM code: 250 and A181), cirrhosis (ICD-9-CM code: 571 and A347), cerebrovascular disease (ICD-9-CM code: 362.34 and 430–438), chronic kidney disease (ICD-9-CM code: 403.11, 403.91, 404.12, 404.92, 585, 586, V42.0, V45.1, V56.0, and V56.8), hypertension (ICD-9-CM code: 401–405, A260, and A269), hyperlipidemia (ICD-9-CM code: 272), coronary artery disease (ICD-9-CM code: 410–414), and chronic obstructive pulmonary disease (ICD-9-CM code: 491, 492, 493, and 496). These common comorbidities were identified when diagnosed prior to the index date. The medications analyzed in this study were statin and calcium channel blocker (CCB) [14, 15]. These medications were identified when prescribed prior to the index date.
Anzeige
Statistical analysis
The chi-square test was used to compare categorical variables between AMD and non-AMD cohorts, whereas the Wilcoxon rank-sum test was used to compare continuous variables between the two cohorts We assessed the overall and age-specific, sex-specific, comorbidity-specific, and medication-specific incidences of PD between the two cohorts. Univariate Cox proportional hazards regression models were used to assess the risk of PD expressed by the hazard ratios (HR) and the 95% confidence intervals (CI). A multivariate Cox proportional hazards regression model was performed with variables, including AMD, sex, age, comorbidities of osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease, chronic obstructive pulmonary disease, and medications of statin and CCB. Cumulative incidence rates of PD in the two cohorts were estimated using Kaplan-Meier methods, and the difference of the cumulative incidence curves of PD between the two cohorts was examined by the log-rank test. Analyses were performed using SAS software (version 9.4 for windows; SAS Institute, Cary, NC, USA) for Windows 10. All statistical significance was set at a p < 0.05.
Results
A total of 20,848 patients were enrolled in the present study. Table 1 demonstrates the distributions of sex, age, comorbidities, and medications between the two cohorts. Both cohorts had similar distributions of age and sex. The mean age (± SD) of the study subjects was 70.4 ± 9.6 years in the AMD cohort and 70.3 ± 9.6 years in the non-AMD cohort (Wilcoxon rank-sum test, p = 0.27). The AMD patients had higher prevalence of all comorbidities than subjects in the non-AMD cohort (p < 0.0001). There was a slightly different drug usage status (statin and CCB) between the two cohorts (p < 0.0001). The follow-up time was also different between the two cohorts (Wilcoxon rank-sum test, p = 0.0002).
Table 1
Baseline characteristics of patients
Age-related Macular Degeneration (n = 10,424)
Non - Age-related Macular Degeneration (n = 10,424)
P-value*
n
%
N
%
Sex
> 0.99
Female
5130
49.2
5130
49.2
Male
5294
50.8
5294
50.8
Age, years
> 0.99
50–59
1732
16.6
1732
16.6
60–69
3087
29.6
3087
29.6
70–79
3841
36.9
3841
36.9
80–100
1764
16.9
1764
16.9
Mean (SD)b
70.4 (9.55)
70.3 (9.63)
0.27
Comorbidity
Osteoporosis
2596
24.9
2017
19.4
< 0.0001
Diabetesa
4918
47.2
3774
36.2
< 0.0001
Cirrhosis
4060
38.9
3092
29.7
< 0.0001
Cerebrovascular disease
2720
26.1
2226
21.3
< 0.0001
Chronic kidney disease
715
6.86
540
5.18
< 0.0001
Hypertension
7418
71.2
6507
62.4
< 0.0001
Hyperlipidemia
4644
44.5
3450
33.1
< 0.0001
Coronary artery disease
792
7.60
589
5.65
< 0.0001
Chronic obstructive pulmonary disease
4238
40.7
3527
33.8
< 0.0001
Numbers of comorbidity
< 0.0001
0
904
8.67
1863
17.87
≥ 1
9520
91.33
8561
82.13
Medications
Statin
8619
82.7
8844
84.8
< 0.0001
CCB
8713
83.6
8683
83.3
< 0.0001
Follow-up time, year (SD)b
5.66 (3.81)
5.48 (3.84)
0.0002
Abbreviations: CCB Calcium Channel Blocker, SD Standard Deviation
*P-value using chi-square for the comparisons between with and without age-related macular degeneration
aDiabetes mellitus included type 1 and type 2 diabetes mellitus
bAverage age and follow-up time using Wilcoxon rank-sum test for verification
Table 2 presents the results of PD risk associated with AMD. AMD patients exhibited a significantly higher risk of subsequent PD, with a crude HR of 1.52 (95% CI = 1.31–1.77). After adjusting all the related covariates, the multivariate Cox proportional hazards regression model indicated an adjusted HR (aHR) of 1.35 (95% CI = 1.15–1.57) for AMD patients compared to the non-AMD cohort. Compared to female patients, male patients had a significant 1.26- (95% CI = 1.07–1.48) fold higher adjusted hazard for PD. Compared to the 50–59 years old age group, the group with 60–69, 70–79, and 80–100 years old subjects had a significant 2.88- (95% CI = 1.91–4.34), 5.12- (95% CI = 3.44–7.62), and 6.12- (95% CI = 4.02–9.31) fold higher adjusted hazard for PD, respectively. Except patients with hyperlipidemia might reduce the risk of PD (aHR = 0.82, 95% CI = 0.69–0.97), patients with diabetes (aHR = 1.21, 95% CI = 1.03–1.42), cerebrovascular disease (aHR = 1.60, 95% CI = 1.36–1.89), and hypertension (aHR = 1.55, 95% CI = 1.27–1.89) could increase the risk of PD. Compared to patients without comorbidity, the aHR of PD was 2.43- (95% CI = 1.76–3.36) fold higher in those with at least one comorbidity. For patients treated with CCB, they were at lower risk of PD.
Table 2
Cox model measured hazard ratios and 95% confidence interval of Parkinson’s disease associated with age-related macular degeneration, sex, age, comorbidity, numbers of comorbidity, and medication
Variable
Parkinson’s disease
Crude HR (95% CI)
Adjusted HR (95% CI)
Event
PY
IR
Age-related Macular Degeneration
No
275
57,168
4.81
1(reference)
1(reference)
Yes
433
59,008
7.34
1.52 (1.31–1.77)***
1.35 (1.15–1.57)***
Sex
Female
306
58,550
5.23
1(reference)
1(reference)
Male
402
57,625
6.98
1.34 (1.15–1.55)***
1.26 (1.07–1.48)**
Age, years
50–59
27
21,129
1.28
1(reference)
1(reference)
60–69
160
37,650
4.25
3.32 (2.21–4.99)***
2.88 (1.91–4.34)***
70–79
364
42,840
8.50
6.66 (4.50–9.85)***
5.12 (3.44–7.62)***
80–100
157
14,556
10.8
8.57 (5.69–12.9)***
6.12 (4.02–9.31)***
P for trend
< 0.0001
< 0.0001
Comorbidity
Osteoporosis
No
526
92,789
5.67
1(reference)
1(reference)
Yes
182
23,387
7.78
1.37 (1.16–1.62)***
1.18 (0.98–1.41)
Diabetes
No
377
72,100
5.23
1(reference)
1(reference)
Yes
331
44,075
7.51
1.44 (1.24–1.67)***
1.21 (1.03–1.42)*
Cirrhosis
No
445
78,977
5.63
1(reference)
1(reference)
Yes
263
37,198
7.07
1.25 (1.08–1.46)**
1.15 (0.98–1.35)
Cerebrovascular disease
No
457
93,109
4.91
1(reference)
1(reference)
Yes
251
23,066
10.88
2.23 (1.91–2.60)***
1.60 (1.36–1.89)***
Chronic kidney disease
No
663
111,329
5.96
1(reference)
1(reference)
Yes
45
4847
9.28
1.57 (1.16–2.12)**
1.09 (0.80–1.48)
Hypertension
No
145
42,494
3.41
1(reference)
1(reference)
Yes
563
73,682
7.64
2.24 (1.87–2.70)***
1.55 (1.27–1.89)***
Hyperlipidemia
No
466
77,239
6.03
1(reference)
1(reference)
Yes
242
38,936
6.22
1.03 (0.88–1.20)
0.82 (0.69–0.97)*
Coronary artery disease
No
649
109,614
5.92
1(reference)
1(reference)
Yes
59
6561
8.99
1.52 (1.16–1.98)**
1.01 (0.77–1.33)
Chronic obstructive pulmonary disease
No
399
77,468
5.15
1(reference)
1(reference)
Yes
309
38,707
7.98
1.55 (1.34–1.80)***
1.07 (0.91–1.25)
Numbers of comorbidity
0
41
18,974
2.16
1(reference)
1(reference)
≥ 1
667
97,201
6.86
3.19 (2.32–4.37)***
2.43 (1.76–3.36)***
Medication
Statin
No
168
26,943
6.24
1(reference)
1(reference)
Yes
540
89,232
6.05
0.97 (0.81–1.16)
0.86 (0.72–1.03)
CCB
No
172
28,424
6.05
1(reference)
1(reference)
Yes
536
87,751
6.11
1.01 (0.85–1.20)
0.77 (0.64–0.93)**
Abbreviations: aHR Adjusted Hazard Ratio estimated by the model including the variables of age-related macular degeneration, sex, age, osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease, chronic obstructive pulmonary disease, statin, and CCB, CCB Calcium Channel Blocker, CI Confidence Interval, HR Hazard Ratio, IR Incidence Rate, per 1000 person-years, PY Person-Years
*p < 0.05; **p < 0.01; ***p < 0.001
Table 3 presents the sex-, age-, comorbidity-, and medication-specific stratified analyses. When stratified by sex, the risk of PD in the AMD cohort was higher in both female (aHR = 1.42, 95% CI = 1.13–1.80) and male patients (aHR = 1.28, 95% CI = 1.05–1.57) compared to the non-AMD cohort. The incidence rate (IR) of PD increased with age in both cohorts, and AMD patients had a significantly higher risk of PD than non-AMD patients in 60–69 (aHR = 1.51, 95% CI = 1.09–2.09), 70–79 (aHR = 1.30, 95% CI = 1.05–1.60), and 80–100 (aHR = 1.40, 95% CI = 1.01–1.95) subgroups. A significant association between increased risk of PD and AMD was observed among patients with comorbidities of osteoporosis (aHR = 1.68, 95% CI = 1.22–2.33), diabetes (aHR = 1.41, 95% CI = 1.12–1.78) and hypertension (aHR = 1.36, 95% CI = 1.15–1.62) and medications of statin (aHR = 1.42, 95% CI = 1.19–1.69) and CCB (aHR = 1.32, 95% CI = 1.11–1.58).
Table 3
Incidence rate and hazard ratio of PD between with and without age-related macular degeneration stratified by sex, age, comorbidity, numbers of comorbidity, and medication
Variable
Age-related Macular Degeneration
Crude HR (95% CI)
Adjusted HR (95% CI)
No
Yes
Event
PY
IR
Event
PY
IR
Sex
Female
115
28,927
3.98
191
29,623
6.45
1.62 (1.29–2.04)***
1.42 (1.13–1.80)**
Male
160
28,240
5.67
242
29,385
8.24
1.45 (1.19–1.78)***
1.28 (1.05–1.57)*
Age, years
50–59
9
10,684
0.84
18
10,445
1.72
2.05 (0.92–4.56)
1.31 (0.57–3.01)
60–69
60
18,836
3.19
100
18,814
5.32
1.67 (1.21–2.30)**
1.51 (1.09–2.09)*
70–79
148
20,681
7.16
216
22,159
9.75
1.36 (1.10–1.68)**
1.30 (1.05–1.60)*
80–100
58
6967
8.32
99
7589
13.0
1.57 (1.14–2.17)**
1.40 (1.01–1.95)*
Comorbidity
Osteoporosis
51
9755
5.23
131
13,631
9.61
1.82 (1.32–2.52)***
1.68 (1.22–2.33)**
Diabetes
109
18,056
6.04
222
26,020
8.53
1.41 (1.12–1.78)**
1.41 (1.12–1.78)**
Cirrhosis
94
15,195
6.19
169
22,003
7.68
1.25 (0.97–1.60)
1.20 (0.93–1.54)
Cerebrovascular disease
92
9742
9.44
159
13,324
11.93
1.27 (0.98–1.64)
1.25 (0.96–1.62)
Chronic kidney disease
18
1942
9.27
27
2904
9.30
1.02 (0.56–1.85)
0.99 (0.54–1.81)
Hypertension
206
33,161
6.21
357
40,520
8.81
1.41 (1.19–1.68)***
1.36 (1.15–1.62)***
Hyperlipidemia
86
15,963
5.39
156
22,973
6.79
1.27 (0.97–1.65)
1.17 (0.90–1.52)
Coronary artery disease
23
2596
8.86
36
3965
9.08
1.02 (0.60–1.71)
1.01 (0.59–1.70)
Chronic obstructive pulmonary disease
117
16,690
7.01
192
22,017
8.72
1.25 (0.99–1.57)
1.19 (0.94–1.50)
Numbers of comorbidity
0
28
12,790
2.19
13
6184
2.10
0.95 (0.49–1.84)
0.95 (0.49–1.85)
≥ 1
247
44,378
5.57
420
52,823
7.95
1.43 (1.22–1.67)*
1.40 (1.20–1.64)***
Medication
Statin
208
44,636
4.66
332
44,596
7.44
1.60 (1.34–1.90)***
1.42 (1.19–1.69)***
CCB
207
42,835
4.83
329
44,916
7.32
1.52 (1.27–1.80)***
1.32 (1.11–1.58)**
Abbreviations: aHR Adjusted Hazard Ratio estimated by the model including the variables of age-related macular degeneration, sex, age, osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease, chronic obstructive pulmonary disease, statin, and CCB, CCB Calcium Channel Blocker, CI Confidence Interval, HR Hazard Ratio, IR Incidence Rate, per 1000 person-years, PY Person-Years
*p < 0.05; **p < 0.01; ***p < 0.001
The association between different types of AMD and risk of PD was further analyzed. Table 4 shows that AMD patients with ICD-9-CM code: 362.50 (Unspecified AMD) had a significantly higher risk of PD (aHR = 1.33, 95% CI = 1.14–1.54) in relation to the non-AMD cohort.
Table 4
Hazard ratio of Parkinson’s disease associated with different types of age-related macular degeneration
Variable
Parkinson’s disease
Crude HR (95%CI)
Adjusted HR (95%CI)
Event
PY
IR
Type of Age-related Macular Degeneration
Unspecified AMD (ICD-9-CM code: 362.50)
No
326
64,236
5.08
1(reference)
1(reference)
Yes
382
51,939
7.35
1.45 (1.25–1.68)***
1.33 (1.14–1.54)***
Non-neovascular AMD (ICD-9-CM code: 362.51)
No
634
107,589
5.89
1(reference)
1(reference)
Yes
74
8587
8.62
1.46 (1.15–1.86)**
1.19 (0.94–1.52)
Neovascular AMD (ICD-9-CM code: 362.52)
No
666
110,575
6.02
1(reference)
1(reference)
Yes
42
5600
7.50
1.25 (0.91–1.70)
1.09 (0.80–1.49)
Abbreviations: aHR Adjusted Hazard Ratio estimated by the model including the variables of age-related macular degeneration, sex, age, osteoporosis, diabetes, cirrhosis, cerebrovascular disease, chronic kidney disease, hypertension, hyperlipidemia, coronary artery disease, chronic obstructive pulmonary disease, statin, and CCB, CCB Calcium Channel Blocker, CI Confidence Interval, HR Hazard Ratio, IR Incidence Rate, per 1000 person-years, PY Person-Years
*p < 0.05; **p < 0.01; ***p < 0.001
Figure 1 demonstrates that the AMD cohort had a higher cumulative incidence of PD than the non-AMD cohort at the end of follow-up (log-rank test, p < 0.0001).
Fig. 1
Using Kaplan-Meier survival statistics, it showed crude overall survival curves by with and without age-related macular degeneration. (log-rank test P < 0.0001)
×
Discussion
Various mechanisms have supported several common conditions linking AMD to PD. First, both diseases are associated with inflammation. For example, a high concentration of complement factors was found in AMD in some studies [16]. Others also supported the role of inflammation and neurodegeneration in AMD and PD [17‐19]. Second, autophagy dysfunction results in the accumulation of misfolded proteins. This is reflected by the aggregation of lipofuscin in RPE cells of AMD patients [20] and alpha-synuclein in neurons of PD patients [21]. Third, both the inflammatory process and autophagy dysfunction will induce oxidative stress, which is another common condition found in AMD and PD as both retina cells and brain cells consume a high proportion of oxygen [22, 23]. When the function of relieving oxidative stress declines due to aging and mitochondrial dysfunction in the RPE of AMD patients and the brain of PD patients, levels of reactive oxygen species and oxidative damage increase.
Structurally, both AMD and PD patients have been reported to undergo thinning of the RNFL [24‐26]. Furthermore, this thinning process was related to the duration of PD. The phenomenon was reported to be due to the loss of retinal dopaminergic amacrine cells and impairment of ganglion cell axons. Based on this finding, the PD rating scale was made to predict the severity of PD based on the thickness of RNFL and other retinal layers by optical coherence tomography [27]. Among these studies, one study reported a different result [28], where there was no difference in retinal thickness between the PD patients and the control group, even though visual acuity and contrast sensitivity were impaired. This could be attributed to the older age of this study group compared to other studies. The average age difference could lead to more difficulties in detecting the different thicknesses of RNFL and the other parts of the retina, since age itself is also a negative factor. Other related studies indicated the potential association between AMD and PD, such as the use of L-DOPA in treating PD that was reported as having a role in preventing AMD [29]. In addition, a lower cognitive function was found among AMD patients [30, 31].
Anzeige
Several studies examined the association between AMD and PD, and all concluded that AMD patients have a higher risk of PD. In 2014, Chung et al. found that neovascular AMD is highly associated with PD during a 3-year follow-up period [8]. They identified 877 cases of neovascular AMD and over 8770 controls between January 1, 2001 and December 31, 2008 in a 3-year follow-up period adjusted for monthly income, geographic region, hypertension, diabetes, hyperlipidemia, and coronary heart disease. All subjects were older than 40 years. The diagnosis of neovascular AMD included ICD-9-CM code 362.42 (serous detachment of RPE), 362.43 (serous detachment of RPE), 362.52 (exudative AMD), and 362.53 (Cystoid macular degeneration). In 2018, Etminan et al. suggested that neovascular AMD may predict the onset of PD [9]. They used the Canadian British Columbia Retinal Disease Database from 2009 to 2013. Neovascular AMD patients undergoing intravitreal injections (bevacizumab or ranibizumab) were included, but only adjusted for age in the cohort study. In 2019, the most updated publication by Choi et al. elucidated that AMD was associated with higher PD risk [10]. They determined 2213 AMD and 306,127 non-AMD follow-up from 2006 to 2013, with adjustment for age, sex, household income, smoking, alcohol, physical activity, BMI, SBP, fasting glucose, total cholesterol, and Charlson comorbidity index. The study defined AMD by ICD-10 coded as H35.3 without specifying neovascular or non-neovascular AMD. Participants were all over 50 years. These three studies above adjusted their lifestyle, socioeconomic status, and clinical conditions.
Our result among non-neovascular and neovascular AMD was different from that of Chung and Etminan [8, 9], but consistent to Choi’s study [10]. The reason might because that our study involved AMD with adjustment for different comorbidities and medications which is similar to Choi et al. [10]. Since the detachment of RPE or cystoid macular edema could be two of clinical features of neovascular AMD but not exclusive ones. Thus, unlike Chung et al. [8], we defined AMD, including unspecific, non-neovascular and neovascular types, as ICD-9-CM codes 362.50, 362.51, and 362.52 rather than as the codes of AMD’s clinical features. In addition, participants younger than 50 years were excluded from our study. In addition, a relatively large number of AMD cases with long follow-up period also offered a more comprehensive result. These may make our result different from that of Chung and Etminan [8, 9], but consistent to Choi study [10].
During the analysis of AMD subtypes (Unspecified, non-neovascular, and neovascular AMD), there was no significant difference in risk of PD. The non-significant difference of PD risk between non-neovascular and neovascular may need further researches stratifying by the disease’s stage since it does not define the stage of AMD by the ICD-9-CM codes as non-neovascular or neovascular AMD. The follow up time in our study started from that AMD was diagnosed rather than the true duration of the disease which might be even longer than the time we recorded. Perhaps the duration or the stage of the AMD might be associated with different degree of the risk of PD.
One of the strengths of our study was the adjustment of sufficient clinical comorbidities and medications related to aging, with a large amount of data that could offer a statistically meaningful outcome. Although we did not adjust the lifestyle, which was proven to be a confounder in the model, comorbidities such as hypertension and hyperlipidemia might also reflect the lifestyle. In addition, the number of AMD patients in our study was relatively large, and the follow-up year was relatively long (5.66 ± 3.81 years in the AMD cohort and 5.48 ± 3.84 years in the non-AMD cohort, from 1998 to 2013). However, there were still limitations to this study. First, the inclusion of cases was based on the data from NHIRD. It was not as accurate as the diagnosis based on diagnostic criteria by researchers themselves. Second, the NHIRD contained mostly Taiwanese patients. Therefore, the result is difficult to generalize globally. Third, it was difficult to separate patients with neovascular and non-neovascular AMD since doctors might only classify them with the general term (ICD-9-CM code 362.50) without specifying the type. This made it impossible to determine the significant association between either type of AMD to the risk of PD due to limited specific data (Table 4). The results were consistent with those of Choi et al., who also compared AMD without specifying the subtype [10]. Fourth, there are other degenerative ocular diseases, such as glaucoma, which are also worth surveying. Further studies are suggested to solve these problems.
Anzeige
In conclusion, we have a result that AMD is associated with a higher risk of PD with adjustment for sufficient clinical comorbidities and long follow-up time. However, further studies for comparing the association between PD and neovascular or non-neovascular AMD during long-term follow-up is needed with more information such as the stage of the disease.
Acknowledgements
Not applicable.
Declarations
Ethics approval and consent to participate
This study adhered to tenets of the Declaration of Helsinki and the ethics committee of China Medical University Hospital reviewed and approved the study.
Consent for publication
Not applicable.
Anzeige
Competing interests
The authors declare no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …
Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …
Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.
Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …
Update Augenheilkunde
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
